Mean age and sex distribution across diagnosesa
| Whole Cohort (n = 97) | Controls (n = 21) | LBD (n = 19) | FTD (n = 20) | AD (n = 20) | MCI (n = 17) | |
|---|---|---|---|---|---|---|
| Mean age (yr) | 65 ± 10 | 60 ± 6 | 72 ± 6 | 64 ± 11 | 72 ± 6 | 62 ± 12 |
| Female (No.) (mean age) (yr) | 45, 46%; 64 ± 11 | 10, 48%; 58 ± 5 | 5, 26%; 74 ± 65 | 10, 50%; 63 ± 13 | 12, 60%; 68 ± 8 | 8, 47%; 60 ± 12 |
| Male (No.) (mean age) (yr) | 52, 54%; 67 ± 10 | 11, 52%; 62 ± 6 | 14, 74%; 72 ± 6 | 10, 50%; 66 ± 9 | 8, 40%; 70 ± 13 | 9, 53%; 64 ± 11 |
| MMSE (mean) | 26 ± 4 | 30 ± 0 | 22 ± 3 | 27 ± 2 | 23 ± 4 | 28 ± 2 |
| Hypertension (No.) (%) | 8 (9) | 3 (14) | 0 | 1 (5) | 2 (10) | 2 (12) |
| Diabetes (No.) (%) | 2 (2) | 1 (5) | 0 | 0 | 1 (5) | 0 |
| Hyperlipidemia (No.) (%) | 6 (7) | 2 (10) | 0 | 1 (5) | 2 (10) | 1 (6) |
| CSF amyloid (median) (IQR) (ng/L) | 575 (403–1250) | 1160 (697–1370) | – | 565 (528–565) | 391 (342–524) | 737 (448–1138) |
| CSF T-τ (median) (IQR) (ng/L) | 52 (36–73) | 274 (211–364) | – | 214 (129–214) | 502 (398–873) | 198 (129–417) |
| CSF P-τ (median) (IQR) (ng/L) | 307 (192–458) | 55 (36–75) | – | 36 (22–36) | 84 (61–115) | 37 (28–67) |
| CSF/serum albumin ratio (median) (IQR) | 249 (153–322) | 230 (166–345) | – | 322 (153–322) | 307 (206–730) | 155 (106–376) |
Note:—P-τ indicates phosphorylated τ; T-τ, total τ; MMSE, Mini-Mental State Examination.
↵a All patients, except 8 with LBD, had data on hypertension, hyperlipidemia, and diabetes. CSF data were available for a subgroup of 56 patients (controls = 18; LBD = 0; FTD = 8; AD = 16; MCI = 14).